AbbVie's SELECT-SLE Study: A Potential Lupus Treatment Breakthrough
ByAinvest
Saturday, Aug 16, 2025 6:48 am ET1min read
ABBV--
AbbVie announced an update on their ongoing Phase 3 clinical study, 'SELECT-SLE,' which evaluates the safety and efficacy of upadacitinib in treating moderately to severely active Systemic Lupus Erythematosus (SLE). Positive results could significantly impact AbbVie's stock performance and expand upadacitinib's market to include SLE, a condition with limited treatment options. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet